New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor ...
– Differentiated SYK-JAK Inhibitor Shows Efficacy in Patients with Heavily Pre-Treated B- and T-Cell Malignancies – – New Signal in AITL; Five Complete Responses for a Complete Response Rate of 71 Percent – – Data to be Presented Monday, June 4, 2018 at …